In Meraouna et al.'s study, the failure-free survival rate was 66% at 3 years of follow-up. Regarding treatment-related morbidities, 12.3% of patients experienced grade 3 genitourinary (GU) toxicity, ...
Over 230 patients enrolled in potential registration-enabling trial in 1L HLA-A2-negative MUM, and median PFS readout targeted by year-end 202595 patients enrolled in neoadjuvant UM trial and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback